A computational investigation has identified the purchasable chemical compound ZINC2770543 as a potential dual-binding lead candidate targeting both epidermal growth factor receptor and Src kinase. Using an integrated virtual screening protocol that combined ligand-based pharmacophore screening, dual-docking refinement, and molecular dynamics simulations, researchers evaluated small-molecule candidates against both oncogenic targets. In comparative simulations, ZINC2770543 demonstrated the most favorable overall binding profile among all evaluated compounds, maintaining stable hydrogen-bond interactions with key amino acid residues in both proteins and yielding favorable binding free energy values relative to standard reference drugs.
The study addresses a major signaling axis implicated in oncogenesis and cancer therapy failure. Src kinase and epidermal growth factor receptor (EGFR) operate as critical mediators within oncogenic signaling cascades that control cellular survival, proliferation, differentiation, and therapeutic resistance.
To discover dual-targeting candidates, the investigators implemented a multi-stage in silico screening strategy that began with ligand-based pharmacophore modeling. Distinct pharmacophore models were constructed for EGFR and Src to capture the critical chemical and spatial features necessary for binding each kinase. These models were then applied to screen purchasable chemical structures cataloged within the ZINC database, identifying hit molecules that matched the pharmacophore specifications of both target receptors.
The hit compounds selected from the pharmacophore screening underwent further structural refinement through molecular docking. The docking workflow utilized two separate computational docking tools, iGEMDOCK version 2.1 and AutoDock version 4.2, to evaluate ligand binding poses and interactions within the target binding sites. To provide a rigorous comparative benchmark, the docking simulations included two established reference inhibitors: erlotinib as the EGFR reference inhibitor and dasatinib as the Src reference inhibitor.
From the molecular docking analysis, six compounds were computationally prioritized as putative dual EGFR and Src binders. This selection was based on binding-pose persistence, specific residue interaction profiles, and comparative Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) binding free energy energetics. Among the prioritized group, ZINC2770543 emerged with the strongest dual-target binding profile. Subsequent molecular dynamics simulations confirmed that ZINC2770543 formed stable hydrogen bonds with essential residues in both EGFR and Src while maintaining advantageous binding free energy metrics compared to erlotinib and dasatinib.
Conducted by researchers at the School of Pharmacy at the Bandung Institute of Technology and published in Frontiers in Drug Discovery, the study provides a computational framework for dual-target lead discovery. The authors caution that the findings reflect in silico predictions and simulation energetics rather than direct biological measurements. Therefore, ZINC2770543 represents a computationally prioritized lead compound that warrants subsequent experimental validation in laboratory assays to verify its actual dual-inhibitory activity.
The investigation, authored by Junaidin Junaidin, Fransiska Kurniawan, and corresponding researcher Daryono Hadi Tjahjono, was formally evaluated within the journal’s section dedicated to in silico methods and artificial intelligence for drug discovery.
Subject of Research: Computational discovery of dual EGFR and Src kinase inhibitor candidates
Article Title: Integrated virtual screening in discovering dual EGFR and Src inhibitor candidates
Article References: Junaidin, J., Kurniawan, F., & Tjahjono, D. H. (2026). Integrated Virtual Screening in Discovering Dual EGFR and Src Inhibitor Candidates. Frontiers in Drug Discovery, 6, 1918390. https://doi.org/10.3389/fddsv.2026.1918390
Image Credits: AI Generated
DOI: 10.3389/fddsv.2026.1918390
Keywords: EGFR, Src kinase, dual-target inhibitors, virtual screening, pharmacophore modeling, molecular docking, molecular dynamics simulations, ZINC database, ZINC2770543, iGEMDOCK, AutoDock, erlotinib, dasatinib, MM/PBSA, binding free energy, oncogenic signaling, therapeutic resistance, in silico drug discovery
News Source: Ophelia Keating. (November 11, 2026). Computational Screening Identifies Candidate Compound ZINC2770543 as Putative Dual EGFR-Src Binder. Scienmag.



